Please ensure Javascript is enabled for purposes of website accessibility

Why Kadmon Holdings Jumped Today

By Prosper Junior Bakiny - May 21, 2020 at 1:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported positive results from a clinical trial for one of its most promising pipeline candidates.

What happened

Shares of Kadmon Holdings (KDMN) are getting a boost on Thursday after the biopharmaceutical company reported positive results from a clinical trial for one of its most promising pipeline candidates, KD025. Kadmon Holdings' stock is up by 8.4% as of 1:05 p.m. today.

So what

KD025 is being investigated as a treatment for chronic graft-versus-host disease (cGVHD), a condition that sometimes manifests itself in a patient following a stem cell transplant and for which there are few treatment options. Today, Kadmon Holdings revealed that the primary analysis of the data from a pivotal clinical trial for KD025 as a treatment for cGVHD revealed that KD025 "achieved clinically meaningful and statistically significant Overall Response Rates."

Hand stacking small wooden blocks in a staircase pattern.

Image Source: Getty Images.

Further, Kadmon Holdings reported positive safety data from the trial; the company said that KD025 "has been well tolerated and adverse events have been consistent with those expected in the patient population." Kadmon Holdings is now looking to send KD025 to the U.S. Food and Drug Administration for review. The company said it should complete a New Drug Application for KD025 in the fourth quarter.

Now what

Kadmon Holdings has a lot riding on KD025. At the moment, the company's products aren't generating much revenue. During its latest reported quarter -- the fourth quarter of its fiscal year 2019 -- Kadmon Holdings recorded $4.4 million in revenue, the majority of which it generated from licensing arrangements and other forms of revenue.

Kadmon Holdings' net sales in that quarter came in at $256 thousand. With this backdrop in mind, it is understandable why investors are excited that Kadmon Holdings looks well on its way to strengthening its lineup. After today's bounce, shares of this pharma company are up by 4.9% year to date.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kadmon Holdings, Inc. Stock Quote
Kadmon Holdings, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.